Drug intelligence / Profile preview

OX125

Development stage: Unknown
Lead developer: Orexo
Modality: Small Molecules
Administration: Intranasal

Overview

OX125 is a clinical-stage intranasal rescue medication developed by Orexo for the treatment of opioid overdose. It consists of a small molecule formulation of nalmefene, a potent opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors to reverse life-threatening respiratory depression. The drug utilizes Orexo's proprietary AmorphOX technology, an intranasal powder-based delivery platform designed for rapid absorption and high bioavailability. Nalmefene's longer half-life compared to naloxone provides a more sustained duration of opioid blockade, which is particularly advantageous for preventing renarcotization (second overdose) and addressing overdoses caused by long-acting synthetic opioids like fentanyl.

Other names: nalmefene

Targets

CD6DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on OX125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OX125.